CDX
HT-29
Tumor indication
Colorectal
Tumor subtype
Colorectal Adenocarcinoma
Description
HT-29 (Colorectal Cancer CDX Model)
The HT-29 colorectal cancer cell line was derived from a human colon adenocarcinoma. It carries a BRAF V600E mutation, a common driver mutation in colorectal cancer. HT-29 is one of the most frequently used colon cancer models in preclinical pipelines. Its reproducibility makes it valuable for translational research.
Key Features:
- Derived from colon adenocarcinoma.
- BRAF V600E mutation.
- Epithelial morphology with glandular features.
- Robust xenograft formation.
Applications:
HT-29 is applied in studies of BRAF-targeted therapies for colorectal cancer. It supports biomarker identification and mechanism-of-action research. Researchers use it to evaluate resistance pathways to chemotherapy. Its genetic stability makes it a benchmark colon cancer model.
Details
- Tumor indication
- Colorectal
- Tumor subtype
- Colorectal Adenocarcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.